{
  "source": "PA-Med-Nec-Epclusa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2090-14\nProgram Prior Authorization/Medical Necessity\nMedication Epclusa® (sofosbuvir/velpatasvir)\nP&T Approval Date 5/2016, 8/2016, 12/2016, 9/2017, 11/2018, 11/2019, 11/2020, 5/2021,\n8/2021, 8/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nEpclusa (sofosbuvir/velpatasvir) is a fixed-dose combination of sofosbuvir, a hepatitis C virus\n(HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor,\nand is indicated for the treatment of adult patients and pediatric patients 3 years of age and older\nwith chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection: 1\n• without cirrhosis or with compensated cirrhosis\n• with decompensated cirrhosis for use in combination with ribavirin\n2. Coverage Criteriaa:\nA. For the treatment of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection, Epclusa will be\napproved based on all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection\n-AND-\n2. One of the following:\na. Patient does not have decompensated liver disease (e.g., Child-Pugh Class B or C)\n-OR-\nb. Both of the following:\n(1) Patient has decompensated liver disease (e.g., Child-Pugh Class B or C)\n-AND-\n(2) Used in combination with ribavirin\n-AND-\n3. Patient is not receiving Epclusa in combination with another HCV direct acting antiviral\nagent [e.g., Mavyret (glecaprevir/pibrentasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\n© 2024 UnitedHealthcare Services Inc.\n1\n-AND-\n4. Physician/provider asserts patient demonstrates treatment readiness, including the\nability to adhere to the treatment regimen\nAuthorization will be issued for 12 weeks.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n•",
    "l regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Epclusa [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2022.\n2. American Association for the Study of Liver Diseases and the Infectious Diseases Society of\nAmerica. Recommendations for Testing, Managing, and Treating Hepatitis C.\nhttps://www.hcvguidelines.org/. Accessed June 5, 2024.\nProgram Prior Authorization/Medical Necessity – Epclusa\n(sofosbuvir/velpatasvir)\nChange Control\nDate Change\n5/2016 New program.\n8/2016 Added step requirement of Harvoni for genotypes 1, 4, 5 or 6 infection.\n11/2016 Added California coverage information.\n12/2016 Removed abstinence-based criteria and replaced with treatment\nreadiness screening criteria. Added Maryland, Indiana and West\nVirginia coverage information.\n5/2017 Administrative update to reorder criteria. State mandate reference\nlanguage updated.\n9/2017 Revised step therapy criteria based on new product availability,\nincluded NY prescriber requirement, removed treatment readiness\nscreening tools and removed medical record submission requirements.\n11/2018 Annual update with no changes to the criteria. Updated references.\n11/2019 Annual update with no changes to the criteria. Updated references.\n11/2020 Annual review. Updated background with no changes to clinical\ncriteria. Updated references.\n5/2021 Removed prescriber requirement. Updated references.\n© 2024 UnitedHealthcare Services Inc.\n2\n8/2021 Updated background with no changes to clinical criteria. Updated\nreferences.\n8/2022 Annual ",
    "s.\n5/2021 Removed prescriber requirement. Updated references.\n© 2024 UnitedHealthcare Services Inc.\n2\n8/2021 Updated background with no changes to clinical criteria. Updated\nreferences.\n8/2022 Annual review. Added Child-Pugh classes for decompensated cirrhosis.\nUpdated references.\n7/2023 Annual review. Updated order of criteria without change to clinical\nintent. Updated references.\n7/2024 Annual review. Removed liver disease staging criteria that was included\nfor quality purposes rather than part of coverage decision. Updated\nreferences.\n© 2024 UnitedHealthcare Services Inc.\n3"
  ]
}